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Abstract
Background: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a bladder disease that causes
debilitating pelvic pain of unknown origin, and IC/PBS symptoms correlate with elevated bladder
lamina propria mast cell counts. Similar to IC/PBS patients, pseudorabies virus (PRV) infection in
mice induces a neurogenic cystitis associated with bladder lamina propria mast cell accumulation
and pelvic pain. We evaluated several drugs to determine the effectiveness of reducing PRV-
induced pelvic pain.
Methods: Neurogenic cystitis was induced by the injection of Bartha's strain of PRV into the
abductor caudalis dorsalis tail base muscle of female C57BL/6 mice. Therapeutic modulation of
pelvic pain was assessed daily for five days using von Frey filament stimulation to the pelvic region
to quantify tactile allodynia.
Results: Significant reduction of PRV-induced pelvic pain was observed for animals treated with
antagonists of neurokinin receptor 1 (NK1R) and histamine receptors. In contrast, the H1R
antagonist hydroxyzine, proton pump inhibitors, a histamine receptor 3 agonist, and gabapentin had
little or no effect on PRV-induced pelvic pain.
Conclusion:  These data demonstrate that bladder-associated pelvic pain is attenuated by
antagonists of NK1R and H2R. Therefore, NK1R and H2Rrepresent direct therapeutic targets for
pain in IC/PBS and potentially other chronic pain conditions.
Background
IC/PBS is a chronic bladder inflammatory disease with
unknown etiology that afflicts as many as 1 million
patients in the United States and is associated with severe
pelvic pain and voiding dysfunction that includes urinary
frequency, urgency, and nocturia [1-3]. Clinical studies
demonstrate elevated mast cell numbers in the lamina
propria of IC/PBS bladder biopsies, and the partial effi-
cacy of neuromodulatory therapies suggests neural-
immune interactions play a role in IC/PBS associated pel-
vic pain ([4,5] and reviewed in [1]). Mast cells contain
preformed stores of immune mediators, such as hista-
mine, and can be activated to release these stores by neu-
rotransmitters such as substance P. These observations
have suggested a central role for mast cells in IC/PBS
pathogenesis whereby activation of bladder-associated
circuits in the central nervous system initiates substance P
release by peripheral nerves in the bladder that then pro-
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motes substance P-mediated mast cell activation [6]. This
mast cell activation, in turn, could release histamine that
acts on nociceptive neurons to induce pelvic pain that
originates from the bladder.
In support of this hypothesis, a subset of IC/PBS patients
exhibit increased density of substance P fibers in the blad-
der sub mucosa with substance P fibers in close proximity
to mast cells [7]. Furthermore, accumulation of lamina
propria mast cells is correlated with IC/PBS symptoms,
and increased levels of urinary histamine metabolites
have been detected in IC/PBS patient urines [4,5,8,9].
These studies suggest that antihistamine treatment may
alleviate IC/PBS associated symptoms, however clinical
trials report varying results. Pilot clinical studies yielded
modest pain relief in IC/PBS patients receiving the old-
line H1R antagonist hydroxyzine [10], but studies have
not yet been conducted with newer generation H1R antag-
onists. In contrast, the H2R antagonist cimetidine pro-
duced significant improvement in pain and nocturia in a
limited trial of PBS patients [11]. In agreement with these
clinical findings, a murine interstitial cystitis model has
demonstrated a requirement for mast cells and histamine
receptors 1 and 2 in pelvic pain originating from the blad-
der (Table 1) [12,13].
Jasmin and colleagues were the first to show that the
attenuated Bartha's strain of pseudorabies virus (PRV)
causes cystitis in rats when injected into the tailbase abduc-
tor caudalis dorsalis muscle [14,15]. PRV is an α-herpesvi-
rus that is taken up by motor neurons and undergoes
retrograde transport to the central nervous system (CNS)
where the virus replicates. PRV-induced cystitis is a neu-
rally mediated cystitis even though Bartha's PRV is incapa-
ble of descending the sensory nerves to the bladder [13-
17]. In mice, PRV causes cystitis in the form of bladder-
specific pathophysiology which includes focal inflamma-
tion, lamina propria mast cell accumulation, the forma-
tion of apoptotic lesions in the urothelium, and a marked
loss of urothelial barrier function [18,19]. In addition,
murine PRV-induced cystitis was also shown to induce
pain specific to the pelvic region in female mice [13]. This
pelvic pain behavior was reduced by intravesical lidocaine
but not by intrauterine lidocaine, suggesting that pelvic
pain behavior was associated with the bladder. Interest-
ingly, colonic lidocaine also relieved pain despite an
absence of detectable bowel pathology, supporting previ-
ous observations of physiologic crosstalk between bladder
and bowel and consistent with food sensitivities exhibited
by IC/PBS patients.
Here, we examined the therapeutic effects of multiple
drugs on pelvic pain in an established murine model that
recapitulates key aspects of IC/PBS, including lamina pro-
pria mast cell accumulation and pelvic pain (see Table 1)
[13,16,18,19]. Pharmacologic antagonism of H2R, H1R
or NK1R attenuated pelvic pain, demonstrating that PRV-
induced pelvic pain is modulated through blocking the
actions of histamine or substance P. In contrast, the H1R
antagonist hydroxyzine, proton pump inhibitors, a hista-
mine receptor 3 agonist, and gabapentin had little or no
effect on PRV-induced pelvic pain. Thus, new generation
H1 antihistamines, H2 antihistamines and NK1R antago-
nists are candidates for expanded clinical trials in the
treatment of IC/PBS associated pain.
Methods
Animals
Adult female C57BL/6J mice (10-14 weeks old) were pur-
chased from Jackson Laboratory (Bar Harbor, ME). All
experiments were performed using protocols approved by
Northwestern University Animal Care and Use Commit-
tee. Mice were housed in containment facilities of the
Center for Comparative Medicine and maintained on a
regular 12:12 hour light:dark cycle with food and water ad
libitum.
Induction of neurogenic cystitis
Pseudorabies virus (PRV) was prepared and titrated as pre-
viously reported in Chen et al 2006 [18]. Neurogenic cys-
titis was induced by injection of 2.29 × 106 pfu Bartha's
PRV through the skin into the abductor caudalis dorsalis
(ACD) muscle using a 26 gauge Hamilton syringe while
maintaining the animals under Isoflurane anesthesia.
Behavioral Testing
Mice were tested prior to PRV administration (baseline),
1, 2, 3 and 4 post infection days (PID) after PRV inocula-
tion. Referred hyperalgesia and tactile allodynia was
tested using von Frey filaments applied to the abdomen
[20]. Mice were tested in individual Plexiglas chambers (6
cm × 10 cm × 12 cm) with a stainless steal wire grid floor
Table 1: Comparison of murine neurogenic cystitis with human IC/PBS.
IC/PBS Murine Cystitis References
Pelvic Specific Pain Yes Yes [1,12,13]
Role for mast cells Yes Yes [4,5,12,16,18,19]
Role for substance P Yes Yes [7], This paper
Role for histamine Yes Yes [9,12]BMC Urology 2009, 9:16 http://www.biomedcentral.com/1471-2490/9/16
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(mouse acclimation period of ~10 min prior to testing).
Frequency of withdrawal responses to the application of
von Frey filaments to the abdomen was tested using five
individual fibers with forces of 0.04, 0.16, 0.4, 1 and 4
grams (Stoelting, USA). Each filament was applied for ~1
second with an inter-stimulus interval of 2-5 s for a total
10 times, and the hairs were tested in ascending order of
force. Stimulation was confined to the lower abdominal
area in the general vicinity of the bladder and care was
taken to stimulate different areas within this region to
avoid desensitization or "wind up" effects. Three types of
behaviors were considered as positive responses to fila-
ment stimulation: (1) sharp retraction of the abdomen;
(2) immediate licking or scratching of the area of filament
stimulation; or (3) jumping.
Therapeutic Treatment
Therapy was initiated 1 hour prior to PRV inoculation and
was repeated every 24 hours until PID 4. Drugs were
administered using the following dosages that were previ-
ously demonstrated as efficacious in murine models: 10
mg/kg Diphenhydramine, 10 mg/kg hydroxyzine, 10 mg/
kg cetirizine, 10 mg/kg cimetidine, 10 mg/kg ranitidine,
10 mg/kg famotidine, 50 mg/kg gabapentin, 12 mg/kg L-
703,606, 5 mg/kg lansoprazole, 5 mg/kg omeprazole and
10 mg/kg imetit (Sigma, St. Louis, MO) was administered
by either oral gavage (Hamiltion syringe with a rounded
tip needle 2.5 cm long) or I.P. (gabapentin, imetit and L-
703,606) [21-25]. PRV-infected mice and sham controls
were gavaged with saline until PID4. All mice were tested
for referred hyperalgesia using von Frey filaments before
PRV (baseline) and PID1-4.
Statistical analyses
Results were expressed as mean ± SEM and analyzed for
statistical significance by single factor ANOVA compared
to baseline values for each filament per group. A value of
p < 0.05 was considered statistically significant.
Results
H1R antihistamine effects on PRV-induced pelvic pain
Pain originating from a visceral organ is typically referred
to a corresponding "dermatome" on the skin that shares
common spinal cord innervation with the given visceral
organ [26]. A role for histamine and histamine receptors
in pain responses has been documented in both humans
and animal models [10,12,27]. To examine H1R as a ther-
apeutic target for pelvic pain, we examined the effects of
pharmacologic antagonists on the development of PRV-
induced pain responses. PRV-infected C57BL/6 female
mice were treated by oral gavage with saline or with anti-
histamines specific for H1R (hydroxyzine, diphenhy-
dramine, or cetirizine). Mice treated with saline alone
exhibited responses to pelvic stimuli that were signifi-
cantly greater than baseline by PID 2, 3 and 4 (Figure 1A;
P < 0.05). Mice treated with the H1R antagonist hydrox-
yzine showed a modest reduction in pelvic sensitivity
(Table 2) that was significantly increased above baseline
by PID 2, 3 and 4 (Figure 1B; P < 0.05). In contrast,
diphenhydramine-treated mice failed to develop signifi-
cant pain until PID 3 and 4 (Figure 1C; P < 0.05) and
developed only 56% of the total pain exhibited by saline-
treated mice (Table 2). Similar to diphenhydramine-
treated mice, cetirizine-treated mice failed to develop sig-
nificant pain until PID 3 and 4 (Fig 1D; P < 0.05) and
developed only 59% of the total pain exhibited by saline-
treated mice (Table 2).
Antihistamines specific for H2R significantly attenuate 
PRV-induced pelvic pain
To evaluate histamine 2 receptor as a therapeutic target for
pelvic pain, we examined the effects of pharmacologic
antagonists on the development of PRV-induced pain
responses. PRV-infected C57BL/6 female mice were
treated by oral gavage with saline or with antihistamines
specific for H2R (cimetidine, ranitidine or famotidine).
Mice treated with saline alone exhibited responses to pel-
vic stimuli that were significantly greater than baseline by
PID 2, 3 & 4 (Figure 2A; P < 0.05). Cimetidine-treated
mice failed to develop significant pain until PID 4 (Figure
2B; P < 0.05) and developed only 42% of the pain exhib-
ited by saline-treated mice (Table 2). In contrast, raniti-
dine-treated mice showed no significant pain responses
relative to baseline at any timepoint (Figure 2C; P > 0.1)
and developed only 23% of the pain exhibited by saline-
treated mice (Table 2). Similar to Cemetidine-treated
mice, famotidine-treated mice failed to develop signifi-
Table 2: Therapeutic modulation of PRV-associated pelvic pain.
Group % Increase* % Relief** P-Value**
Experiment 1
Saline 392.4 ± 39.6 0
Hydroxyzine 383.9 ± 123.9 2 P < 0.96
Diphenhydramine 222.4 ± 74.7 44 P < 0.08
Cetirizine 230.6 ± 52.8 41 P < 0.06
Experiment 2
Saline 431.7 ± 92.4 0
Cimetidine 182.4 ± 43.3 58 P < 0.02
Ranitidine 101.0 ± 37.5 77 P < 0.005
Famotidine 167.3 ± 35.1 61 P < 0.02
Experiment 3
Saline 498.8 ± 112.7 0
Gabapentin 371.7 ± 136.7 25 P < 0.50
L-703,606 116.7 ± 55.8 77 P < 0.02
Experiment 4
Saline 388.1 ± 69.5 0
Lansoprazole 394.0 ± 44.7 0 P < 0.95
Omeprazole 368.7 ± 68.6 5 P < 0.85
Imetit 454.3 ± 111.8 0 P < 0.63
*at PID4 relative to baseline **at PID4 relative to salineBMC Urology 2009, 9:16 http://www.biomedcentral.com/1471-2490/9/16
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Antihistamines specific for H1 receptor attenuate pelvic pain Figure 1
Antihistamines specific for H1 receptor attenuate pelvic pain. A) Female mice treated by oral gavage with saline 
exhibited significantly increased pelvic sensitivity relative to baseline at PID 2, 3 and 4 for all filaments tested (n = 8, P < 0.05). 
B) Female mice treated by oral gavage with the H1R antagonist hydroxyzine showed a modest reduction in pelvic sensitivity 
that was significantly increased above baseline by PID 2, 3 and 4 (n = 9, P < 0.05). C) Female mice treated by oral gavage with 
the H1R antagonist diphenhydramine showed reduced pelvic sensitivity that was not significantly increased above baseline until 
PID 3 and 4 (n = 9, P < 0.05). D) Female mice treated by oral gavage with the H1R antagonist cetirizine showed reduced pelvic 
sensitivity that was not significantly increased above baseline until PID 3 and 4 (n = 9, P < 0.05). The symbol key shown in (A) 
applies to panels A-D. Error bars depict SEM, and significance was determined by ANOVA.
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Antihistamines specific for H2 receptor attenuate pelvic pain Figure 2
Antihistamines specific for H2 receptor attenuate pelvic pain. A) Female mice treated by oral gavage with saline 
exhibited significantly increased pelvic sensitivity relative to baseline at PID 2, 3 and 4 for all filaments tested (n = 8, P < 0.05). 
B) Female mice treated by oral gavage with the H2R antagonist cimetidine showed reduced pelvic sensitivity that was not sig-
nificantly increased above baseline until PID 4 (n = 10, P < 0.05). C) Female mice treated by oral gavage with H2R antagonist 
ranitidine did not develop significant pelvic sensitivity (n = 10). D) Female mice treated by oral gavage with the H2R antagonist 
famotidine showed reduced pelvic sensitivity that was not significantly increased above baseline until PID 4 (n = 10, P < 0.05). 
The symbol key shown in (A) applies to panels A-D. Error bars depict SEM, and significance was determined by ANOVA.
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cant pain until PID 4 (Figure 2D; P < 0.05) and developed
only 49% of the pain exhibited by saline-treated mice
(Table 2). These data demonstrate that PRV-induced pel-
vic pain can be significantly attenuated by H2R antago-
nists.
Neural therapies differentially attenuate PRV-induced 
pelvic pain
We examined an NK1R antagonist and gabapentin on the
development of PRV-induced pain responses. PRV-
infected C57BL/6 female mice were treated I.P. with
saline, the NK1R antagonist L-703,606 or gabapentin.
Mice treated with saline alone exhibited responses to pel-
vic stimuli that were significantly greater than baseline by
PID 2, 3 & 4 (Figure 3A; P < 0.05). Gabapentin-treated
mice failed to develop significant pain until PID 3 and 4
(Fig 3B; P < 0.05) and developed 74% of the pain exhib-
ited by saline-treated mice (Table 2). In contrast, L-
703,606-treated mice showed no significant pain
responses relative to baseline at any timepoint (Figure 3C;
P > 0.1) and developed only 23% of the pain exhibited by
saline-treated mice (Table 2), similar to ranitidine-treated
mice. These data demonstrate that PRV-induced pelvic
pain can be significantly attenuated by a NK1R antago-
nist.
Proton pump inhibitors have minimal or no effect on PRV-
induced pelvic pain
To evaluate proton pumps and H3R agoninsts as thera-
peutic targets for pelvic pain, we examined the effects of
pharmacologic antagonists on the development of PRV-
induced pain responses. PRV-infected C57BL/6 female
mice were treated by oral gavage with saline, with proton-
pump inhibitors (lansoprazole or omeprazole) or an H3R
agonist (imetit). Mice treated with saline alone exhibited
responses to pelvic stimuli that were significantly greater
than baseline by PID 2, 3 & 4 (data not shown). Mice
treated with the lansoprazole, omeprazole or imetit
showed little or no reduction in pelvic sensitivity (Table
2) that was significantly increased above baseline by PID
3 (data not shown). These data demonstrate that PRV-
induced pelvic pain is not significantly attenuated by pro-
ton-pump inhibitors or H3R agonist.
Discussion
In a murine model of IC/PBS that recapitulates pelvic spe-
cific pain, we find that pelvic pain can be modulated by
the neural-immune axis through blocking the actions of
histamine or substance P. Previously, we showed that
PRV-induced pelvic pain is mediated by mast cells via
H1R and H2R, using both genetic and pharmacologic
approaches [12]. We expanded these observations in this
study by demonstrating that both famotidine and cimeti-
dine can attenuate pelvic pain similar to ranitidine, how-
ever ranitidine is the most effective, reducing 77% of the
pelvic pain (Table 2). We also find that the substance P
receptor antagonist, L-703,606, attenuated pelvic pain by
77% demonstrating it to be as effective a ranitidine (Table
2). Furthermore blocking H1R with diphenhydramine
and cetirizine reduced pelvic pain by at least 40%,
Substance P receptor antagonist and gabapentin attenuate pelvic pain Figure 3
Substance P receptor antagonist and gabapentin attenuate pelvic pain. A) Female mice treated with saline (I.P.) 
exhibited significantly increased pelvic sensitivity relative to baseline at PID 2, 3 and 4 for all filaments tested (n = 5, P < 0.05). 
B) Female mice treated with gabapentin (I.P.) showed reduced pelvic sensitivity that was not significantly increased above base-
line until PID 3 (n = 5, P < 0.05). C) Female mice treated with a substance P receptor antagonist L-703,606 did not develop sig-
nificant pelvic sensitivity (n = 6). The symbol key shown in (A) applies to panels A-C. Error bars depict SEM, and significance 
was determined by ANOVA.
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whereas the old generation H1R antagonist hydroxyzine
had only a modest reduction in pelvic pain (Table 2). In
contrast to our previous study, however, diphenydramine
pain blockade failed to achieve statistical robustness here
(P < 0.08) due to unusual variability. One possible influ-
ence is unforeseen environmental factors, as the animal
containment facilities necessary for PRV studies have relo-
cated to a new building. Nonetheless, while these results
emphasize the statistical vagaries inherent in small animal
sample sizes, the findings here are consistent with our pre-
vious report. Conversely, proton pump inhibitors, hista-
mine receptor 3 agonist, and gabapentin had little or no
effect on PRV-induced pelvic pain (Table 2). These data
identify histamine 1 and 2 receptors and neurokinin 1
receptor as therapeutic targets for direct intervention in
pelvic pain of IC/PBS.
Our data support a model of IC/PBS pathogenesis involv-
ing a positive feedback loop as originally postulated by
Theoharides and Elbadawi, whereby substance P-contain-
ing peripheral nerves stimulate mast cells, in turn releas-
ing histamine that induces pain originating from the
bladder [6,9]. Furthermore, histamine release by mast
cells feeds back onto peripheral nerves to cause sustained
release of substance P in the periphery to prolong mast
cell activation or in the spinal cord to prolong neuronal
excitation. This model is consistent with murine neuro-
genic cystitis and a subset of IC/PBS patients [7]. We find
that the substance P receptor antagonist, L-703,606, atten-
uated pelvic pain behavior by 77% (Table 2). L-703,606,
could be acting in the periphery to block substance P
induction of mast cell-derived histamine and subsequent
activation of pain fibers. Alternatively, L-703,606 could be
acting in the spinal cord to block neuron-derived sub-
stance P activation of dorsal horn neurons that mediate
pain. Regardless of the mechanism, our data demonstrate
that blocking substance P attenuates pelvic pain in murine
neurogenic cystitis and is a novel therapeutic target for
direct intervention in pelvic pain.
We previously observed isolectin B4-positive processes
within the lamina propria, where mast cells accumulate in
IC/PBS and our murine IC model [4,5,18], suggesting that
interactions between mast cell histamine and C fiber noci-
ceptors mediate pelvic pain in this IC/PBS model. This is
reminiscent of an esophagitis model where mast cell his-
tamine stimulates C fiber activity via H1R, therefore it is
possible that histamine may act on bladder sensory nerves
in IC/PBS because histamine metabolites are increased in
IC/PBS urine [9,28]. This mechanism is similar to patients
with irritable bowel syndrome where abdominal/pelvic
pain is correlated with activated colonic mucosal mast
cells in proximity to nerves, and colonic tissue extracts
that contained elevated histamine that excited rat nocice-
ptors [29]. These findings support the idea that neural-
immune interactions can mediate pain in multiple pelvic
pain syndromes.
Our evidence for histamine-mediated pelvic pain pro-
vides a mechanistic understanding of previous clinical
findings. The H2R antagonist cimetidine produced signif-
icant improvement in pain and nocturia in a limited trial
of IC/PBS patients [11], however clinical trials have yet to
be conducted with ranitidine or famotidine. Similarly,
pilot clinical studies yielded modest pain relief in IC/PBS
patients receiving the old-line H1R antagonist hydrox-
yzine (Atarax) [10], but studies have not yet been con-
ducted with newer generation H1R antagonists like
diphenhydramine or cetirizine. Modern H1R antagonists
likely attenuated pelvic pain better here than older gener-
ation H1R antagonists because newer H1R antagonists are
well-absorbed, act faster, have greater efficacy, and a
longer duration of action [30]. We have previously shown
that H1R and H2R are expressed in both the bladder and
colon of mice, leaving the possibility of the H1R and H2R
antihistamines acting at either or both of the organs to
quell pelvic pain. Additionally, the colon modulates PRV-
induced pelvic pain, pelvic organs generally exhibit neu-
ral-mediated crosstalk, and IBS is a co-morbidity of IC/
PBS [13,31]. Therefore, these epidemiologic and animal
model findings together suggest that H1R and H2R antag-
onists may have general application for the treatment of
pelvic pain.
Conclusion
These findings support a general model for IC/PBS pelvic
pain due to mast cell-sensory nerve interactions. Pharma-
cologic antagonism of H1R, H2R or NK1R attenuated pel-
vic pain, blocking the actions of histamine or substance P
represent therapeutic targets for direct intervention in pel-
vic pain. Thus, new generation H1 antihistamines, H2
antihistamines and NK1R antagonists are candidates for
expanded clinical trials in the treatment of pain associated
with IC/PBS.
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